Angela L Patterson, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 130 E Harbin Ave, Puxico, MO 63960 Phone: 573-222-3556 |
News Archive
Many patients with rare, fast-growing neuroendocrine tumors respond well to a common immunotherapy drug combination, according to the first peer-reviewed publication out of DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, a unique rare cancer clinical trial.
Former U.S. Senate Majority Leader Bill Frist (R-Tenn.) and Habitat for Humanity CEO Jonathan Reckford write in an Atlanta Journal-Constitution opinion piece about the need to "address the constant crisis families face daily in deplorable living conditions."
Clinical Genomics, a private company developing innovative diagnostic tools for colorectal cancer, today announced that data supporting its two-gene circulating tumor DNA (ctDNA) blood test for post-surgical monitoring of colorectal cancer (CRC) recurrence have been published online by Cancer Medicine, and will appear in the October issue.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 2 days ago